open access

Vol 8, No 2 (2012)
Review paper
Published online: 2012-06-27
Get Citation

Modulators of bone turn-over in the treatment of patients with bone metastases

Piotr Wysocki
Onkol. Prak. Klin 2012;8(2):76-83.

open access

Vol 8, No 2 (2012)
REVIEW ARTICLES
Published online: 2012-06-27

Abstract

Bone metastases are a frequent complication of cancer, occurring in up to 70% of patients with advanced
breast or prostate cancer. Skeletal-related events involving pathological fractures, spinal cord compression
and a need for surgery/radiotherapy, which are frequently observed in cancer patients with bone
metastases have a detrimental effect on patients’ survival and quality of life. Therefore, prevention of
skeletal-related events is a crucial element in cancer treatment. The aim of this article was to summarize
data on approved bone-modifying agents used for treatment of cancer patients with bone metastases. In
breast cancer patients with bone metastases, several bisphosphonates and denosumab demonstrated
clinical efficacy, but in the case of bone metastases from prostate cancer or other solid tumors only zoledronic
acid and denosumab were clinically active. It is important to mention, that despite their significant
clinical efficacy neither bisphosphonates nor denosumab demonstrated any positive impact on survival
of patients with bone metastases.

Abstract

Bone metastases are a frequent complication of cancer, occurring in up to 70% of patients with advanced
breast or prostate cancer. Skeletal-related events involving pathological fractures, spinal cord compression
and a need for surgery/radiotherapy, which are frequently observed in cancer patients with bone
metastases have a detrimental effect on patients’ survival and quality of life. Therefore, prevention of
skeletal-related events is a crucial element in cancer treatment. The aim of this article was to summarize
data on approved bone-modifying agents used for treatment of cancer patients with bone metastases. In
breast cancer patients with bone metastases, several bisphosphonates and denosumab demonstrated
clinical efficacy, but in the case of bone metastases from prostate cancer or other solid tumors only zoledronic
acid and denosumab were clinically active. It is important to mention, that despite their significant
clinical efficacy neither bisphosphonates nor denosumab demonstrated any positive impact on survival
of patients with bone metastases.
Get Citation

Keywords

bisphosphonates, denosumab, bone metastases, brest cancer, prostate cancer

About this article
Title

Modulators of bone turn-over in the treatment of patients with bone metastases

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 2 (2012)

Article type

Review paper

Pages

76-83

Published online

2012-06-27

Bibliographic record

Onkol. Prak. Klin 2012;8(2):76-83.

Keywords

bisphosphonates
denosumab
bone metastases
brest cancer
prostate cancer

Authors

Piotr Wysocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl